Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Ovarian Neoplasms 55 Small Cell Lung Carcinoma 39 Lung Neoplasms 30 Carcinoma, Ovarian Epithelial 29 Neuroblastoma 25 Fallopian Tube Neoplasms 23 Uterine Cervical Neoplasms 18 Neoplasms 18 Leukemia 18 Leukemia, Myeloid, Acute 14 Precursor Cell Lymphoblastic Leukemia-Lymphoma 13 Sarcoma 10 Lymphoma 10 Brain Neoplasms 9 Recurrence 8 Carcinoma, Non-Small-Cell Lung 8 Unspecified Adult Solid Tumor, Protocol Specific 7 Neoplasm Metastasis 7 Myelodysplastic Syndromes 7 Burkitt Lymphoma 7 Blast Crisis 7 Neuroectodermal Tumors, Primitive, Peripheral 6 Lymphoma, Non-Hodgkin 6 Lymphoma, Large B-Cell, Diffuse 6 Lymphoma, Follicular 6 Leukemia, Myelomonocytic, Chronic 6 Leukemia, Myelomonocytic, Acute 6 Leukemia, Monocytic, Acute 6 Leukemia, Megakaryoblastic, Acute 6 Leukemia, Erythroblastic, Acute 6

Interventions

Nivolumab 13 Surveys and Questionnaires 6 Ipilimumab 6 linrodostat 5 Standard of Care 5 Paclitaxel 5 Bevacizumab 5 Sirolimus 4 Pemetrexed 4 Interviews as Topic 4 Gemcitabine 4 Docetaxel 4 ARRY-334543 4 temsirolimus 3 relatlimab 3 Erlotinib Hydrochloride 3 Cetuximab 3 Carboplatin 3 regorafenib 2 anlotinib 2 abemaciclib 2 Vorinostat 2 Trastuzumab 2 Sorafenib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Magnetic Resonance Spectroscopy 2 Doxorubicin 2 Dasatinib 2 Cyclophosphamide 2 vorolanib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Advanced Cancer × Topotecan × Clear all

NCT00770731 2013-02-13

Study of Temsirolimus, Topotecan, and Bortezomib

M.D. Anderson Cancer Center

Phase 1 Completed

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡